AU5136093A - Peptide antagonists of sh2 binding and therapeutic uses thereof - Google Patents

Peptide antagonists of sh2 binding and therapeutic uses thereof

Info

Publication number
AU5136093A
AU5136093A AU51360/93A AU5136093A AU5136093A AU 5136093 A AU5136093 A AU 5136093A AU 51360/93 A AU51360/93 A AU 51360/93A AU 5136093 A AU5136093 A AU 5136093A AU 5136093 A AU5136093 A AU 5136093A
Authority
AU
Australia
Prior art keywords
binding
therapeutic uses
peptide antagonists
antagonists
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51360/93A
Inventor
Ellen M. Dobrusin
Derek Maclean
Dennis J. Mcnamara
Alan R Soltiel
Andrea Thieme-Sefler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU5136093A publication Critical patent/AU5136093A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU51360/93A 1992-09-25 1993-09-22 Peptide antagonists of sh2 binding and therapeutic uses thereof Abandoned AU5136093A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95124192A 1992-09-25 1992-09-25
US951241 1992-09-25
US12202893A 1993-09-15 1993-09-15
US122028 1993-09-15
PCT/US1993/008996 WO1994007913A1 (en) 1992-09-25 1993-09-22 Peptide antagonists of sh2 binding and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
AU5136093A true AU5136093A (en) 1994-04-26

Family

ID=26820076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51360/93A Abandoned AU5136093A (en) 1992-09-25 1993-09-22 Peptide antagonists of sh2 binding and therapeutic uses thereof

Country Status (2)

Country Link
AU (1) AU5136093A (en)
WO (1) WO1994007913A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710074B1 (en) 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa GRB3-3 gene, its variants and their uses.
US6066463A (en) * 1993-09-28 2000-05-23 New York University Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
AU4972096A (en) * 1995-02-01 1996-08-21 Affymax Technologies N.V. Peptides and compounds that bind to sh2 domains
AU4440596A (en) * 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of hcp SH2 specific compounds to enhance erythropoiesis
CA2212645A1 (en) * 1995-02-10 1996-08-15 Damien John Dunnington Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
US5688992A (en) * 1995-03-31 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US6280964B1 (en) * 1995-04-14 2001-08-28 The Regents Of The University Of California Binding sites for phosphotyrosine binding domains
JP2000514036A (en) * 1995-06-30 2000-10-24 スミスクライン・ビーチャム・コーポレイション Use of a Stat 6 SH2 domain specific compound to treat an allergic reaction
WO1997002024A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
GB9516842D0 (en) * 1995-08-17 1995-10-18 Ciba Geigy Ag Various acylated oligopeptides
GB9517060D0 (en) * 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives
US6303319B1 (en) 1996-02-23 2001-10-16 Ariad Pharmaceuticals, Inc. Cell based assay for identifying sh2-domain-specific signal transducer antagonist
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
CA2239463A1 (en) * 1996-11-01 1998-05-14 Onyx Pharmaceuticals, Inc. Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
WO1998024902A1 (en) * 1996-12-03 1998-06-11 Sugen, Inc. Adaptor protein frs2 and related products and methods
CA2343934A1 (en) 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
US7226991B1 (en) 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
EP1163262B1 (en) 1999-03-23 2011-05-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Phenylalanine derivatives
US7871981B2 (en) 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
WO2001028577A2 (en) 1999-10-22 2001-04-26 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
EP1383792A2 (en) 2000-08-22 2004-01-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Sh2 domain binding inhibitors
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
EP1682571A4 (en) * 2003-10-27 2006-12-06 Medvet Science Pty Ltd A bidentate motif and methods of use
WO2006069001A2 (en) * 2004-12-20 2006-06-29 Baylor College Of Medicine Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands
US9029146B2 (en) 2005-09-02 2015-05-12 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
US8242080B2 (en) * 2006-10-13 2012-08-14 The Regents Of The University Of California Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface
WO2009105044A1 (en) 2008-02-22 2009-08-27 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles
SG188918A1 (en) 2008-03-17 2013-04-30 Agency Science Tech & Res
EP2496711B1 (en) 2009-11-02 2016-02-17 Agency For Science, Technology And Research Methods for monitoring cellular states and for immortalizing mesenchymal stem cells
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
US9528994B2 (en) 2011-07-25 2016-12-27 The Regents Of The University Of California Target of the phosphoinositide 3-kinase pathway
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
US20190231694A1 (en) 2016-10-12 2019-08-01 Agency For Science, Technology And Research Method for lyophilising an exosome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171407B1 (en) * 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
CA2054602C (en) * 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system

Also Published As

Publication number Publication date
WO1994007913A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
AU5136093A (en) Peptide antagonists of sh2 binding and therapeutic uses thereof
AU673703B2 (en) Injector and use of the same
AU692612B2 (en) Peptide mixture and products thereof
EP0785276A4 (en) Modification of peptide and protein
AU5793396A (en) Human interferon tau compositions and methods of use
EP0880356A4 (en) Antimicrobial peptides and methods of use
AU6709596A (en) Amide compounds and use of the same
AU1618697A (en) Novel compounds and pharmaceutical use thereof
GB9414925D0 (en) Electrode and preparation thereof
AU6360394A (en) Vasonatrin peptide and analogs thereof
ZA967654B (en) Electrodes and methods of preparation thereof
GB9521544D0 (en) Activation of P53 protein and therapeutic applications thereof
AU4463996A (en) Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
AU1159897A (en) Analogs of peptide yy and uses thereof
HUP9901343A3 (en) P53 protein variants and therapeutical uses thereof
AU6428890A (en) Therapeutic peptides and proteins
AU3461095A (en) Compositions and methods for delivery of polypeptides
AU4305897A (en) Pharmaceutical compositions containing amisulpride and therapeutic applications thereof
AU4382693A (en) Therapeutic uses of pungent botanicals and their related compounds
AU7000896A (en) Novel peptide compounds and medicinal compositions thereof
AU3350197A (en) Mixture of esters and use thereof
AU7529796A (en) S-nitroso-hemoglobin and therapeutic uses thereof
AU2512495A (en) Therapeutic phenoxyalkylazoles and phenoxyalkylazines
AU5548694A (en) Peptide inhibitors of tyrosine kinases and therapeutic uses thereof
AU2154695A (en) Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof